1. Home
  2. AKBA vs RDNW Comparison

AKBA vs RDNW Comparison

Compare AKBA & RDNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo RideNow Group Inc.

RDNW

RideNow Group Inc.

HOLD

Current Price

$6.40

Market Cap

290.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
RDNW
Founded
2007
2013
Country
United States
United States
Employees
N/A
1906
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
290.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AKBA
RDNW
Price
$1.21
$6.40
Analyst Decision
Strong Buy
Hold
Analyst Count
3
2
Target Price
$4.67
$6.50
AVG Volume (30 Days)
5.7M
152.3K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.01
Revenue Next Year
N/A
$6.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$2.98
52 Week High
$4.08
$8.55

Technical Indicators

Market Signals
Indicator
AKBA
RDNW
Relative Strength Index (RSI) 65.77 36.17
Support Level $1.16 $6.28
Resistance Level $1.56 $7.09
Average True Range (ATR) 0.08 0.52
MACD 0.03 -0.08
Stochastic Oscillator 87.69 11.98

Price Performance

Historical Comparison
AKBA
RDNW

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About RDNW RideNow Group Inc.

RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.

Share on Social Networks: